These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 2748528

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers.
    Fleishaker JC, Phillips JP.
    Psychopharmacology (Berl); 1989; 99(1):34-9. PubMed ID: 2506603
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.
    Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, Greenblatt DJ.
    J Clin Pharmacol; 2005 May; 45(5):529-37. PubMed ID: 15831776
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in health volunteers.
    Fleishaker JC, Hulst LK, Smith TC, Friedman H.
    Eur J Clin Pharmacol; 1992 May; 42(3):287-94. PubMed ID: 1577047
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administration.
    Fleishaker JC, Wright CE.
    Pharm Res; 1992 Apr; 9(4):457-63. PubMed ID: 1495889
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects.
    Hulhoven R, Desager JP, Cox S, Harvengt C.
    Eur J Clin Pharmacol; 1988 Apr; 35(1):59-64. PubMed ID: 3220095
    [Abstract] [Full Text] [Related]

  • 15. Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumping.
    Fleishaker JC, Phillips JP, Lau HS.
    Biopharm Drug Dispos; 1990 Nov; 11(8):715-27. PubMed ID: 2271747
    [Abstract] [Full Text] [Related]

  • 16. Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.
    Fleishaker JC, Friedman H, Pollock SR.
    Pharm Res; 1991 Feb; 8(2):162-7. PubMed ID: 2023863
    [Abstract] [Full Text] [Related]

  • 17. Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder.
    Fleishaker JC, Greist JH, Jefferson JW, Sheridan AQ.
    J Clin Psychopharmacol; 1994 Feb; 14(1):28-35. PubMed ID: 8151001
    [Abstract] [Full Text] [Related]

  • 18. N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10-50 mg oral doses in healthy volunteers.
    Fleishaker JC, Smith TC, Friedman H, Phillips JP.
    Psychopharmacology (Berl); 1991 Feb; 105(2):181-5. PubMed ID: 1796125
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.